In addition, the overall survival rate of patients with advanced gastric adenocarcinomas remains low, despite the use of new targeted agents like the human epidermal growth-factor receptor 2 (HER2) antibody (trastuzumab)51. This evidence concerns the gene ERBB2 and gastric adenocarcinoma.